"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2004/094250 A1,035-315-906-084-156,2004-11-04,2004,MX 2004000026 W,2004-04-07,MX JL03000014 A,2003-04-22,FOLDING CRATE,"The invention relates to a rectangular folding crate comprising at least five elements which are interarticulated by means of a simple assembly system. The aforementioned system enables the constituent parts of the invention to be replaced if necessary and enables said parts to be completely dismantled and flattened such as to optimise use of space for storage purposes. In addition, the invention comprises securing devices such that the crate can be fixed in the final shape thereof for the storage of goods such as fruit and vegetables. The invention also comprises a removable protective element which can be positioned on the surface of same in order to offer operational advantages. Moreover, the upper and lower faces of the crate comprise a channel which enables an equal number of crates having the same characteristics to be connected above and below same.",BETANCOURT RUELAS ALEJANDRO;;PADILLA RAMIREZ FRANCISCO JAVI,BETANCOURT RUELAS ALEJANDRO;;PADILLA RAMIREZ FRANCISCO JAVI,,https://lens.org/035-315-906-084-156,Patent Application,yes,7,6,2,2,0,B65D11/1833;;B65D11/1873;;B65D85/345,B65D6/22;;B65D85/34,,0,0,,,,PENDING
2,MX,A,MX 2012006856 A,012-636-253-139-000,2013-12-16,2013,MX 2012006856 A,2012-06-14,MX 2012006856 A,2012-06-14,PROCESS FOR OBTAINING NANOCOMPOSITE SUPERMAGNETS WITH TWO MAGNETIC PHASES AND COMPLEX GEOMETRIES.,"Process for obtaining permanent supermagnets, both isotropic and anisotropic, for facilitating the obtention of pieces with profiles of different shapes, both regular and irregular, using quick solidification for acquiring the base alloy, followed by severe deformation by extrusion. As part of the process, a device of severe deformation by extrusion is described, which does not require the application of elevated temperatures, allowing the obtained structure to be maintained by quick solidification, thus obtaining supermagnets with increased mechanic and magnetic properties, which are used in the manufacture of speakers, uniform and non-uniform magnetic field sources; magnetic couplings; levitation systems; actuators; sensors; DC, synchrony and stepper motors; magnet-therapy; sensors for storing data and for different electronic devices such as printers, cameras and clocks; biomedical devices, such as cardiac valves, magnetic catheters, dental devices and sensors for the automotive in dustry.",UNIV MEXICO NACIONAL AUTONOMA,VARGAS IGNACIO ALEJANDRO FIGUEROA;;REYES JOSE ISRAEL BETANCOURT;;LOPEZ ISMELI ALFONSO,,https://lens.org/012-636-253-139-000,Patent Application,no,0,0,2,2,0,,B22F3/20;;H01F7/02;;H01F41/02,,0,0,,,,ACTIVE
3,MX,B,MX 367888 B,114-158-667-975-935,2019-08-27,2019,MX 2012006856 A,2012-06-14,MX 2012006856 A,2012-06-14,PROCESS FOR OBTAINING NANOCOMPOSITE SUPERMAGNETS WITH TWO MAGNETIC PHASES AND COMPLEX GEOMETRIES.,"Process for obtaining permanent supermagnets, both isotropic and anisotropic, for facilitating the obtention of pieces with profiles of different shapes, both regular and irregular, using quick solidification for acquiring the base alloy, followed by severe deformation by extrusion. As part of the process, a device of severe deformation by extrusion is described, which does not require the application of elevated temperatures, allowing the obtained structure to be maintained by quick solidification, thus obtaining supermagnets with increased mechanic and magnetic properties, which are used in the manufacture of speakers, uniform and non-uniform magnetic field sources; magnetic couplings; levitation systems; actuators; sensors; DC, synchrony and stepper motors; magnet-therapy; sensors for storing data and for different electronic devices such as printers, cameras and clocks; biomedical devices, such as cardiac valves, magnetic catheters, dental devices and sensors for the automotive in dustry.",UNIV MEXICO NAC AUTONOMA,IGNACIO ALEJANDRO FIGUEROA VARGAS;;JOSÉ ISRAEL BETANCOURT REYES;;ISMELI ALFONSO LÓPEZ,,https://lens.org/114-158-667-975-935,Granted Patent,no,0,0,2,2,0,,B22F3/20;;H01F7/02;;H01F41/02,,0,0,,,,ACTIVE
4,CO,U1,CO 2017012629 U1,034-715-989-796-816,2018-12-14,2018,CO 2017012629 U,2017-12-07,CO 2017012629 U,2017-12-07,Centros de atencion inteligentes e interactivos,"La presente invención se caracteriza por ser CENTROS DE ATENCIÓN INTELIGENTE E INTERACTI VOS, fijos, o móviles en áreas públicas o privadas que pertenecen al sector de las comunicaciones y la tecnología proporcionando todo tipo de información, gubernamental, policial, pedagógica, comercial e institucional en tiempo real. Este sistema de CENTRO DE ATE NCION INTELIGENTES E INTERACTIVOS se encuentra entrelazado con un canal dedicado de internet, con el fin de tener soluciones tecnológicas e innovadoras para mejorar los procesos de respuesta a las necesidades urbanas conectadas a centrales de comunicaciones (DATA CENTER) fijos o móviles integrando a toda una ciudad, caracterizándose para prestar un mejor funcionamiento, y agilidad en respuestas en tiempo real, dotado de comunicaciones de ciber seguridad, cámaras ubicadas estratégicamente para generar un circuito cerrado por medio de cámaras de: Video vigilancia, cámaras caza infractores cámaras de reconocimiento facial, cámara conteo de personas, lectura de placas, de igual manera cuenta con sistemas para la verificación de antecedentes, (personas y vehículos), registro biométrico (huellero digital), conectividad a internet, equipos de audio y de visualización con pantallas monitores. lcd. led y táctiles para la realización de actividades y comunicación pedagógica y comercial. Servicios informativos de movilidad, comercial, turística, institucional, pedagógica, gubernamental, sistemas de alertas y botones de pánico, conectadas con el centro de gestión y policía más cercano. Los CENTRO DE ATENCIÓN INTELIGENTES E INTERACTIVOS generan toda una minería de datos y se caracteriza por acceso a aplicaciones (App) interactuando por medio móviles, tablet portátiles, etc., auto sostenibles, con un sistema de energía solar, mejorando la calidad de vida de los ciudadanos y usuarios del sistema.",SEGURA RODRIGUEZ ALEJANDRO,SEGURA RODRIGUEZ ALEJANDRO;;MALDONADO GONZÁLEZ JESÚS ALFREDO;;SEGURA BETANCOURT PAULA ANDREA;;SEGURA BETANCOURT JUAN SEBASTIAN;;CUARTAS JIMENEZ JHONY DANIEL,,https://lens.org/034-715-989-796-816,Unknown,no,0,0,1,1,0,,G06Q30/00;;G06Q30/02;;G06Q50/00,,0,0,,,,PENDING
5,MX,A,MX 2017003889 A,130-365-352-444-904,2018-09-24,2018,MX 2017003889 A,2017-03-24,MX 2017003889 A,2017-03-24,ZINC OXIDE NANOPARTICLES SYNTHESIS PROCESS TO REGENERATE SKIN IN WOUNDS OR CUTANEOUS INJURIES.,"The present disclosure is related to a novel process for the synthesis of zinc oxide nanoparticles (NPs), to be applied in the skin to regenerate the same from wounds or skin lesions. Zinc oxide NPs are obtained with the process suggested in the present invention with a size of 25 to 230 nanometers and a purity of 98%. These NPs are applied in a solution at a concentration of 200 ppm and up to 4,000 ppm on diabetic foot wounds, varicose ulcers, inter alia; regenerating the skin in a time of 4 to 10 weeks. During this time, the Zinc oxide NPs obtained with the synthesis process of the present invention, regenerating the tissue and reducing the proliferation of pathogenic microorganisms that can infect the wound. The present invention is directed to the industrial sector, specifically to the nanoparticle synthesis, cosmetics, and health sector: pharmaceutical and the biomedical industries, inter alia.",CENTRO DE INVESTIGACION EN QUIM APLICADA,PABLO GONZÁLEZ MORONES;;BERTHA ALICIA PUENTE URBINA;;JOSE ALEJANDRO DIAZ ELIZONDO;;REBECA BETANCOURT GALINDO,,https://lens.org/130-365-352-444-904,Patent Application,no,0,0,1,1,0,,C01G9/02;;A61K33/08;;A61K33/30,,0,0,,,,PENDING
6,WO,A1,WO 2020/141004 A1,171-601-938-489-922,2020-07-09,2020,CO 2019000015 W,2019-12-18,CO 2018014418 A,2018-12-31,DEPLOYABLE SOLAR PANEL SYSTEM WITH A POSITIONING MECHANISM FOR CAPTURING SUNLIGHT,The present invention relates to a structural system with an arrangement of solar panels that are deployed and guided towards the sunlight automatically by means of a solar tracker.,VELASQUEZ SALGADO JESUS ALEJANDRO;;ZAMBRANO BUSTACARA ROSENDO;;ARBULU SAAVEDRA MARIO RICARDO;;BETANCOURT ORTIZ ROBERTO JESUS,VELÁSQUEZ SALGADO JESÚS ALEJANDRO;;ZAMBRANO BUSTACARA ROSENDO;;ARBULÚ SAAVEDRA MARIO RICARDO;;BETANCOURT ORTÍZ ROBERTO JESÚS,,https://lens.org/171-601-938-489-922,Patent Application,yes,4,0,2,2,0,F24S20/50;;F24S30/45;;F24S30/48;;H02S20/30;;H02S20/32;;H02S30/20;;Y02E10/47;;Y02E10/50,F24S20/50;;F24S30/45;;F24S30/48;;H02S20/30;;H02S20/32,,0,0,,,,PENDING
7,PT,E,PT 1803447 E,069-899-857-591-842,2009-08-14,2009,PT 04774809 T,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,,PSICOFARMA S A DE C V,FLORES LUIS ESTRADA;;GONZALEZ ALFONSO DUENAS;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO MOHAR,,https://lens.org/069-899-857-591-842,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
8,WO,A1,WO 2006/028362 A1,104-449-748-758-091,2006-03-16,2006,MX 2004000064 W,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,"The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",PSICOFARMA S A DE C V;;ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/104-449-748-758-091,Patent Application,yes,3,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,3,2,089-916-354-336-556;;089-916-354-336-556,14088963;;10.1002/jps.2600521210;;14088963;;10.1002/jps.2600521210,"""Mexican Pharmacopoeia"";;HIGUCHI T.: ""Mechanism of Sustained-action Medication. Theoretical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices"", J PHARM SCI., vol. 52, December 1963 (1963-12-01), pages 1145 - 9;;HIGUCHI T, J PHARM SCI., vol. 52, December 1963 (1963-12-01), pages 1145 - 9",PENDING
9,NZ,A,NZ 554360 A,091-924-249-875-082,2009-11-27,2009,NZ 55436004 A,2004-09-09,MX 2004000064 W,2004-09-09,Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment,"Disclosed is a hydralazine extended release pharmaceutical composition consisting of: a) from 16 to 20% hydralazine hydrochloride as active ingredient; b) from 42 to 44% of a polymer that limits the release rate of said active ingredient wherein said polymer is hydroxypropylmethylcellulose; c) from 25 to 28% of a diluent agent wherein the diluent agent is microcrystalline cellulose; d) from 10% of a release rate-moderating hydrophilic polymer wherein said polymer is pregelatinized starch; and e) from 0.1 to 2% of a lubricant where said lubricant agents is magnesium stearate, or a) from 16 to 20% hydralazine hydrochloride as active ingredient; b) from 44 to 46% of a polymer that limits the release rate of said active ingredient wherein said polymer is hydroxypropylmethylcellulose; c) from 27 to 29% of a diluent agent wherein the diluent agent is microcrystalline cellulose; d) from 10% of a release rate-moderating hydrophilic polymer wherein said polymer is pregelatinized starch; and e) from 0.1 to 2% of a lubricant where said lubricant agents is magnesium stearate. Disclosed is the use of a hydralazine extended release pharmaceutical composition according to any one of claims 1 or 2, in the manufacture of a medicament useful in the treatment of cancer, wherein the releases rates are up to 10.823 mg/h or 10.323 mg/h for 20-22 hours.",PISCOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/091-924-249-875-082,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22;;A61K31/498;;A61P35/00,,0,0,,,,DISCONTINUED
10,BR,A,BR PI0419032 A,017-460-890-887-410,2007-12-11,2007,BR PI0419032 A,2004-09-09,MX 2004000064 W,2004-09-09,composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do cáncer,"COMPOSIçãO FARMACêUTICA DE LIBERAçãO PROLONGADA DE HIDRALAZINA E SEU USO COMO APOIO PARA O TRATAMENTO DO CáNCER. A presente invenção se refere a uma forma de liberação prolongada de hidralazina para se utilizar na terapia contra o câncer. Esta forma de liberação prolongada de hidralazina permite que se alcance no sangue uma concentração constante do princípio ativo que permite que se apresente o efeito desmetilante da hidralazina sem que apareça sua ação hipotensora, o que permite seu uso na terapia contra o câncer.",PSICOFARMA S A DE C V,FLORES LUIS ESTRADA;;GONZALEZ ALFONSO DUENAS;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO MOHAR,,https://lens.org/017-460-890-887-410,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
11,SI,T1,SI 1803447 T1,100-873-846-456-692,2010-01-29,2010,SI 200431198 T,2004-09-09,EP 04774809 A;;MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,,PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/100-873-846-456-692,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/00,,0,0,,,,ACTIVE
12,CY,T1,CY 1110508 T1,110-627-105-338-735,2015-04-29,2015,CY 091101053 T,2009-10-13,EP 04774809 A;;MX 2004000064 W,2004-09-09,ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΓΙΑ ΤΗΝ ΠΑΡΑΤΕΙΝΟΜΕΝΗ ΕΚΛΥΣΗ ΥΔΡΑΛΑΖΙΝΗΣ ΚΑΙ ΧΡΗΣΗ ΑΥΤΗΣ ΩΣ ΥΠΟΣΤΗΡΙΚΤΙΚΟ ΜΕΣΟ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ,"Η εφεύρεση αναφέρεται σε μια μορφή παρατεινόμενης έκλυσης υδραλαζίνης για χρήση στην θεραπεία του καρκίνου. Η αναφερόμενη μορφή παρατεινόμενης έκλυσης υδραλαζίνης μπορεί να χρησιμοποιηθεί για να λαμβάνεται μια σταθερή συγκέντρωση του ενεργού συστατικού μέσα στο αίμα, καθιστώντας έτσι δυνατή την επίδραση απομεθυλίωσης της υδραλαζίνης χωρίς να παράγεται η υποτασική επίδραση αυτής, έτσι ώστε η σύνθεση της εφεύρεσης να μπορεί να χρησιμοποιηθεί σε θεραπεία του καρκίνου.",PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUEÑAS GONZÁLEZ ALFONSO;;BORBOLLA GARCÍA ARTURO;;SERNA MARTÍNEZ RAÚL;;RIVERA HERNÁNDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/110-627-105-338-735,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
13,BR,B1,BR PI0419032 B1,113-882-562-722-721,2019-02-05,2019,BR PI0419032 A,2004-09-09,MX 2004000064 W,2004-09-09,composição farmacêutica de liberação prolongada de hidralazina,"composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do câncer. a presente invenção se refere a uma forma de liberação prolongada de hidralazina para se utilizar na terapia contra o câncer. esta forma de liberação prolongada de hidralazina permite que se alcance no sangue uma concentração constante do princípio ativo que permite que se apresente o efeito desmetilante da hidralazina sem que apareça sua ação hipotensora, o que permite seu uso na terapia contra o câncer.",PSICOFARMA S A DE C V,ALEJANDRO MOHAR BETANCOURT;;ALFONSO DUEÑAS GONZÁLEZ;;ALFREDO RIVERA HERNÁNDEZ;;ARTURO BORBOLLA GARCÍA;;LUIS ESTRADA FLORES;;RAÚL SERNA MARTÍNEZ,,https://lens.org/113-882-562-722-721,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
14,MX,A,MX 2007002871 A,141-085-485-631-861,2007-04-23,2007,MX 2007002871 A,2007-03-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT.,"The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",PSICOFARMA S A DE C V,GONZALEZ ALFONSO DUENAS;;FLORES LUIS ESTRADA;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO HAR,,https://lens.org/141-085-485-631-861,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/00,,0,0,,,,ACTIVE
15,DE,D1,DE 602004022205 D1,000-813-166-593-589,2009-09-03,2009,DE 602004022205 T,2004-09-09,MX 2004000064 W,2004-09-09,PHARMAZEUTISCHE ZUSAMMENSETZUNG FÜR DIE VERZÖGERTE FREISETZUNG VON HYDRALAZIN UND IHRE VERWENDUNG ALS UNTERSTÜTZUNG ZUR KREBSTHERAPIE,,PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/000-813-166-593-589,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
16,CA,C,CA 2579220 C,018-948-650-539-340,2013-01-08,2013,CA 2579220 A,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,"The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/018-948-650-539-340,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
17,DK,T3,DK 1803447 T3,022-412-333-954-865,2009-10-12,2009,DK 04774809 T,2004-09-09,MX 2004000064 W,2004-09-09,Farmaceutisk sammensætning til vedvarende frisætning af hydralazin og anvendelse heraf som en understötning for cancerbehandling,,PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;MOHAR BETANCOURT ALEJANDRO;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO,,https://lens.org/022-412-333-954-865,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
18,KR,A,KR 20070061833 A,063-527-035-630-157,2007-06-14,2007,KR 20077006815 A,2007-03-26,KR 20077006815 A,2007-03-26,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,"The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/063-527-035-630-157,Patent Application,no,0,0,1,1,0,A61K9/2013;;A61K9/2054;;A61K9/2059,A61K9/22,,0,0,,,,DISCONTINUED
19,EP,B1,EP 1803447 B1,043-781-418-558-357,2009-07-22,2009,EP 04774809 A,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,,PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/043-781-418-558-357,Granted Patent,yes,1,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,3,1,134-431-659-082-862,12738711,"DINSHEET ET AL: ""Preparation and Evaluation of Muco-adhesive Buccal Tablets of Hydralazine Hydrochloride"", INDIAN J. PHARM SCI., vol. 59, no. 3, 1997, pages 135 - 144;;SEGURA-PACHECO ET AL: ""Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and their Potential Use"", CANCER THERAPY, CLINICAL CANCER RESEARCH, vol. 9, 2003, pages 1596 - 1603;;BILAC ET AL: ""Studies on Prolonged Release Matrix Tablet Formulations of Hydralazine Hydrochloride"", ACTA PHARMACEUTICAL TURCICA, vol. 45, pages 11 - 15",ACTIVE
20,CA,A1,CA 2579220 A1,043-858-438-066-248,2006-03-16,2006,CA 2579220 A,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,,PSICOFARMA S A DE C V,DUENAS GONZALEZ ALFONSO;;ESTRADA FLORES LUIS;;MOHAR BETANCOURT ALEJANDRO;;RIVERA HERNANDEZ ALFREDO;;SERNA MARTINEZ RAUL;;BORBOLLA GARCIA ARTURO,,https://lens.org/043-858-438-066-248,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
21,ES,T3,ES 2330227 T3,064-632-812-845-656,2009-12-07,2009,ES 04774809 T,2004-09-09,MX 2004000064 W,2004-09-09,COMPOSICION FARMACEUTICA DE LIBERACION PROLONGADA DE HIDRALAZINA Y SU USO COMO APOYO PARA EL TRATAMIENTO DE CANCER.,"La presente invención se refiere a una forma de liberación prolongada de hidralazina para utilizarse en la terapia contra el cáncer. Esta forma de liberación prolongada de hidralazina permite quese alcance en sangre una concentración constante del principio activo que permite que se presente el efecto desmetilante de la hidralazina sin que aparezca su acción hipotensora, lo que permitesu uso en la terapia contra el cáncer.",PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/064-632-812-845-656,Granted Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
22,BR,B8,BR PI0419032 B8,081-718-403-086-04X,2021-05-25,2021,BR PI0419032 A,2004-09-09,MX 2004000064 W,2004-09-09,composição farmacêutica de liberação prolongada de hidralazina,"composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do câncer. a presente invenção se refere a uma forma de liberação prolongada de hidralazina para se utilizar na terapia contra o câncer. esta forma de liberação prolongada de hidralazina permite que se alcance no sangue uma concentração constante do princípio ativo que permite que se apresente o efeito desmetilante da hidralazina sem que apareça sua ação hipotensora, o que permite seu uso na terapia contra o câncer.",PSICOFARMA S A DE C V,ALEJANDRO MOHAR BETANCOURT;;ALFONSO DUEÑAS GONZÁLEZ;;ALFREDO RIVERA HERNÁNDEZ;;ARTURO BORBOLLA GARCÍA;;LUIS ESTRADA FLORES;;RAÚL SERNA MARTÍNEZ,,https://lens.org/081-718-403-086-04X,Amended Patent,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
23,EP,A1,EP 1803447 A1,014-875-410-768-603,2007-07-04,2007,EP 04774809 A,2004-09-09,MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,"The invention relates to a sustained release form of hydralazine for use in cancer theraphy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/014-875-410-768-603,Patent Application,yes,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,ACTIVE
24,NI,A,NI 200700072 A,039-652-383-510-605,2008-04-24,2008,NI 200700072 A,2007-03-09,NI 200700072 A,2007-03-09,COMPOSICIÓN FARMACÉUTICA DE LIBERACIÓN PROLONGADA DE HIDRALAZINA Y SU USO COMO APOYO PARA EL TRATAMIENTO DEL CÁNCER,"La presente invención se refiere a una forma de liberación prolongada de hidralazina para utilizarse en la terapia contra el cáncer. Esta forma de liberación prolongada de hidralazina permite que se alcance en sangre una concentración constante del principio activo que permite que se presente el efecto desmetilante de la hidralazina sin que aparezca su acción hipotensora, lo que permite su uso en la terapia contra el cáncer.",PSICOFARMA S A DE C V,FLORES LUIS ESTRADA;;GONZALEZ ALFONSO DUENAS;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO MOHAR,,https://lens.org/039-652-383-510-605,Granted Patent,no,0,0,1,1,0,,A61K9/22,,0,0,,,,ACTIVE
25,US,B2,US 7820200 B2,057-206-500-237-955,2010-10-26,2010,US 57501607 A,2007-10-12,MX 2004000064 W,2004-09-09,Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment,"The invention relates to a substained release form of hydralazine for use in cancer therapy. The substained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.",FLORES LUIS ESTRADA;;GONZALEZ ALFONSO DUENAS;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO MOHAR,FLORES LUIS ESTRADA;;GONZALEZ ALFONSO DUENAS;;GARCIA ARTURO BORBOLLA;;MARTINEZ RAUL SERNA;;HERNANDEZ ALFREDO RIVERA;;BETANCOURT ALEJANDRO MOHAR,PSICOFARMA S.A. DE C.V (2007-02-21),https://lens.org/057-206-500-237-955,Granted Patent,yes,3,2,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,424/468,0,0,,,,ACTIVE
26,CR,A,CR 9035 A,075-694-553-469-248,2009-03-27,2009,CR 9035 A,2007-04-09,MX 2004000064 W,2004-09-09,COMPOSICION FARMACEUTICA DE LIBERACION PROLONGADA DE HIDRALAZINA Y SU USO COMO APOYO PARA EL TRATAMIENTO DE CANCER,"La presente invencion se refiere a una forma de liberacion prolongada de hidralazina para utilizarse en la terapia contra el cancer. Esta forma de liberacion prolongada de hidralazina permite que se alcance en sangre una concentracion constante del principio activo que permite que se presente el efecto de desmetilante de la hidralazina sin que aparezca su accion hipotensora, lo que permite su uso en la terapia contra el cancer.",PSICOFARMA S A DE C V,LUIS ESTRADA FLORES;;ALFONSO DUENAS GONZALEZ;;ARTURO BORBOLLA GARCIA;;RAUL SERNA MARTINEZ;;ALFREDO RIVERA HERNANDEZ;;ALEJANDRO MOHAR BETANCOURT,,https://lens.org/075-694-553-469-248,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,DISCONTINUED
27,EC,A,EC SP077377 A,038-767-445-881-027,2007-05-30,2007,EC SP077377 A,2007-04-09,EC SP077377 A,2007-04-09,COMPOSICIÓN FARMACÉUTICA DE LIBERACIÓN PROLONGADA DE HIDRALAZINA Y SU USO COMO APOYO PARA EL TRATAMIENTO DE CÁNCER,"La presente invención se refiere a una forma de liberación prolongada de hidralazina para utilizarse en la terapia contra el cáncer. Esta forma de liberación prolongada de hidralazina permite que se alcance en sangre una concentración constante del principio activo que permite que se presente el efecto desmetilante de la hidralazina sin que aparezca su acción hipotensora, lo que permite su uso en la terapia contra el cáncer.",SICOFARMA SA,ESTRADA FLORES LUIS;;DUENAS GONZALEZ ALFONSO;;BORBOLLA GARCIA ARTURO;;SERNA MARTINEZ RAUL;;RIVERA HERNANDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/038-767-445-881-027,Patent Application,no,0,0,1,1,0,,A61K9/22,,0,0,,,,PENDING
28,PL,T3,PL 1803447 T3,172-663-084-299-358,2010-05-31,2010,PL 04774809 T,2004-09-09,EP 04774809 A;;MX 2004000064 W,2004-09-09,PHARMACEUTICAL COMPOSITION FOR THE SUSTAINED RELEASE OF HYDRALAZINE AND USE THEREOF AS A SUPPORT FOR CANCER TREATMENT,,PSICOFARMA S A DE C V,ESTRADA FLORES LUIS;;DUEÑAS GONZÁLEZ ALFONSO;;BORBOLLA GARCÍA ARTURO;;SERNA MARTÍNEZ RAÚL;;RIVERA HERNÁNDEZ ALFREDO;;MOHAR BETANCOURT ALEJANDRO,,https://lens.org/172-663-084-299-358,Patent Application,no,0,0,23,23,0,A61K9/2013;;A61K9/2054;;A61K9/2059;;A61P35/00;;A61K9/2054;;A61K9/2013;;A61K9/2059,A61K9/22,,0,0,,,,PENDING
29,CO,A1,CO 2022006525 A1,031-731-666-183-610,2022-06-21,2022,CO 2022006525 A,2022-05-17,CO 2022006525 A,2022-05-17,Dispositivo para entrenamiento de radiología intervencionista,"La presente invención revela un dispositivo compuesto por un conjunto de piezas configurables para entrenamiento de médicos. El dispositivo de la invención permite, especialmente, a los residentes en radiología intervencionista, perfeccionar sus habilidades motrices en el manejo del instrumental quirúrgico que involucra procedimientos vasculares, como el de cateterismo. La configuración del dispositivo de la invención permite simular el procedimiento con elementos y equipos reales integrado a partes análogas y digitales que simulan el sistema vascular del ser humano.",UNIV ICESI;;FUND VALLE DEL LILI,BETANCOURT VELASCO MARIA CLARA;;GARCIA DANIELA;;GRANADOS SANCHEZ ANA MARÍA;;ARAÚJO MEJIA CARLOS HUMBERTO;;OREJUELA ZAPATA JUAN FELIPE;;SALAZAR BALCÁZAR ALEJANDRO,,https://lens.org/031-731-666-183-610,Patent Application,no,0,0,1,1,0,,G09B23/28;;G06F1/00;;G09B23/00;;G09B23/30,,0,0,,,,PENDING
30,US,A1,US 2021/0097337 A1,022-653-114-495-475,2021-04-01,2021,US 201916669170 A,2019-10-30,US 201916669170 A;;US 201962906720 P,2019-09-27,USER-GENERATED VISUAL GUIDE FOR THE CLASSIFICATION OF IMAGES,"Systems and methods are disclosed herein for creating a visual guide for developing training data for a classification of image, where the training data includes images tagged with labels for the classification of the images. A processor may prompt a user to define a framework for the classification. For an initial set of images within the training data, qualified human classifiers are prompted to locate the images within the framework and to tag the images with labels. The processor determines whether the tagged images have consistent labels, and, if so, the processor adds images to the training data. The processor may add the images by providing a visual guide, the visual guide including tagged images arranged according to their locations within the framework their labels, and prompting human classifiers to tag the additional images with labels for the classification, according to the visual guide.",LANDING AI,WANG DONGYAN;;GOPAL GOPI PRASHANTH;;NG ANDREW YAN-TAK;;NATHILLVAR KARTHIKEYAN THIRUPPATHISAMY;;HASHIMOV RUSTAM;;HE PINGYANG;;LAIRD DILLON ANTHONY;;RONG YIWEN;;BETANCOURT ALEJANDRO;;SATHEESH SANJEEV;;ZHOU YU QING,LANDING AI LLC (2024-01-24);;LANDING AI (2020-07-08);;LANDING AI INC (2023-03-31),https://lens.org/022-653-114-495-475,Patent Application,yes,0,0,5,5,0,G06N20/00;;G06V10/945;;G06V10/774;;G06N20/00;;G06N5/04;;G06F18/41;;G06F18/214;;G06F18/217;;G06V10/774;;G06V10/945,G06N5/04;;G06N20/00;;G06V10/774,,0,0,,,,ACTIVE
31,US,B2,US 11182646 B2,036-378-442-403-992,2021-11-23,2021,US 201916669170 A,2019-10-30,US 201916669170 A;;US 201962906720 P,2019-09-27,User-generated visual guide for the classification of images,"A process and a system for creating a visual guide for developing training data for a classification of image, where the training data includes images tagged with labels for the classification of the images. A processor may prompt a user to define a framework for the classification. For an initial set of images within the training data, qualified human classifiers are prompted to locate the images within the framework and to tag the images with labels. The processor determines whether the tagged images have consistent labels, and, if so, the processor adds images to the training data. The processor may add the images by providing a visual guide, the visual guide including tagged images arranged according to their locations within the framework their labels, and prompting human classifiers to tag the additional images with labels for the classification, according to the visual guide.",LANDING AI,WANG DONGYAN;;GOPAL GOPI PRASHANTH;;NG ANDREW YAN-TAK;;NATHILLVAR KARTHIKEYAN THIRUPPATHISAMY;;HASHIMOV RUSTAM;;HE PINGYANG;;LAIRD DILLON ANTHONY;;RONG YIWEN;;BETANCOURT ALEJANDRO;;SATHEESH SANJEEV;;ZHOU YU QING,LANDING AI LLC (2024-01-24);;LANDING AI (2020-07-08);;LANDING AI INC (2023-03-31),https://lens.org/036-378-442-403-992,Granted Patent,yes,7,0,5,5,0,G06N20/00;;G06V10/945;;G06V10/774;;G06N20/00;;G06N5/04;;G06F18/41;;G06F18/214;;G06F18/217;;G06V10/774;;G06V10/945,G06N5/04;;G06N20/00;;G06V10/774,,1,0,,,"PCT International Search Report and Written Opinion, PCT Application No. PCT/US2020/052299, dated Jan. 13, 2021, 13 pages.",ACTIVE
32,US,A1,US 2022/0277171 A1,023-157-968-446-937,2022-09-01,2022,US 202117500784 A,2021-10-13,US 202117500784 A;;US 201916669170 A;;US 201962906720 P,2019-09-27,USER-GENERATED VISUAL GUIDE FOR THE CLASSIFICATION OF IMAGES,"Systems and methods are disclosed herein for creating a visual guide for developing training data for a classification of image, where the training data includes images tagged with labels for the classification of the images. A processor may prompt a user to define a framework for the classification. For an initial set of images within the training data, qualified human classifiers are prompted to locate the images within the framework and to tag the images with labels. The processor determines whether the tagged images have consistent labels, and, if so, the processor adds images to the training data. The processor may add the images by providing a visual guide, the visual guide including tagged images arranged according to their locations within the framework their labels, and prompting human classifiers to tag the additional images with labels for the classification, according to the visual guide.",LANDING AI,WANG DONGYAN;;GOPAL GOPI PRASHANTH;;NG ANDREW YAN-TAK;;NATHILLVAR KARTHIKEYAN THIRUPPATHISAMY;;HASHIMOV RUSTAM;;HE PINGYANG;;LAIRD DILLON ANTHONY;;RONG YIWEN;;BETANCOURT ALEJANDRO;;SATHEESH SANJEEV;;ZHOU YU QING,LANDING AI (2020-07-08);;LANDING AI INC (2024-01-24),https://lens.org/023-157-968-446-937,Patent Application,yes,0,0,5,5,0,G06N20/00;;G06V10/945;;G06V10/774;;G06N20/00;;G06N5/04;;G06F18/41;;G06F18/214;;G06F18/217;;G06V10/774;;G06V10/945,G06N5/04;;G06N20/00;;G06V10/774,,0,0,,,,ACTIVE
33,US,B2,US 11790270 B2,102-348-473-330-559,2023-10-17,2023,US 202117500784 A,2021-10-13,US 202117500784 A;;US 201916669170 A;;US 201962906720 P,2019-09-27,User-generated visual guide for the classification of images,"A process and a system for creating a visual guide for developing training data for a classification of image, where the training data includes images tagged with labels for the classification of the images. A processor may prompt a user to define a framework for the classification. For an initial set of images within the training data, qualified human classifiers are prompted to locate the images within the framework and to tag the images with labels. The processor determines whether the tagged images have consistent labels, and, if so, the processor adds images to the training data. The processor may add the images by providing a visual guide, the visual guide including tagged images arranged according to their locations within the framework their labels, and prompting human classifiers to tag the additional images with labels for the classification, according to the visual guide.",LANDING AI,WANG DONGYAN;;GOPAL GOPI PRASHANTH;;NG ANDREW YAN-TAK;;NATHILLVAR KARTHIKEYAN THIRUPPATHISAMY;;HASHIMOV RUSTAM;;HE PINGYANG;;LAIRD DILLON ANTHONY;;RONG YIWEN;;BETANCOURT ALEJANDRO;;SATHEESH SANJEEV;;ZHOU YU QING,LANDING AI (2020-07-08);;LANDING AI INC (2024-01-24),https://lens.org/102-348-473-330-559,Granted Patent,yes,7,0,5,5,0,G06N20/00;;G06V10/945;;G06V10/774;;G06N20/00;;G06N5/04;;G06F18/41;;G06F18/214;;G06F18/217;;G06V10/774;;G06V10/945,G06F18/21;;G06F18/214;;G06F18/40;;G06N5/04;;G06N20/00;;G06V10/774;;G06V10/94,,2,0,,,"PCT International Search Report and Written Opinion, PCT Application No. PCT/US2020/052299, dated Jan. 13, 2021, 13 pages.;;United States Office Action, U.S. Appl. No. 16/669,170, filed Apr. 29, 2021, 22 pages.",ACTIVE
34,MX,A,MX 2015017404 A,197-978-484-595-635,2017-06-15,2017,MX 2015017404 A,2015-12-16,MX 2015017404 A,2015-12-16,PROCESS FOR OBTAINING POLYMIRCENE COMPOSITIONS USING NEODYMIUM BASED CATALYTIC SYSTEMS.,"The present disclosure is related to a composition process for obtaining polymircene by solution coordination polymerization, using different tertiary catalytic systems based on neodymium. Each of them comprises the following components: Catalytic system I) neodymium versatate (Nd)/tri isobutyl aluminum (Al)/diethyl aluminum chloride (Cl); Catalytic system 2) neodymium isopropoxide (Nd)/tri isobutyl aluminum (Al )N, N dimethyl aniline tetrakis (pentafluorophenyl) borate (B). The variation of the ratios in each Al/Nd and c1/Nd catalytic system as well as B/Nd and Al/Nd, allows modifying the final and performance characteristics of the polymircenes.",CENTRO DE INVESTIG EN QUIM APLICADA,HORTENSIA MALDONADO TEXTLE;;ENRIQUE JAVIER JIMENEZ REGALADO;;REBECA BETANCOURT GALINDO;;JESUS ALEJANDRO ESPINOZA MUÑOZ;;HECTOR RICARDO LOPEZ GONZALEZ;;RAMON ENRIQUE DIAZ DE LEON GOMEZ;;RICARDO MENDOZA CARRILZALES;;FRANCISCO JAVIER ENRIQUEZ MEDRANO;;MARCELINA SANCHEZ ADAME,,https://lens.org/197-978-484-595-635,Patent Application,no,0,0,1,1,0,,B01J23/10;;B01J21/02,,0,0,,,,PENDING
35,EP,A3,EP 0864649 A3,021-950-763-056-952,1998-11-11,1998,EP 98202021 A,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,"A multi-step process for recovering hepatitis B surface antigen from  Pichia pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CIGB,MUZIO GONZALEZ VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO J;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/021-950-763-056-952,Search Report,yes,1,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
36,AU,B2,AU 649482 B2,053-590-339-987-592,1994-05-26,1994,AU 1991/085574 A,1991-10-03,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,,CIGB,GONZALEZ VERENA L MUCIO;;ARIAS EDUARDO PENTON;;ESCOBAR GIUVEL FONTIRROCHI;;GALVEZ MARCELO NAZABAL;;GRIEGO MARTA DE JESUS GONZALEZ;;IZNAGA ALEJANDRO BELDARRAIN;;GONZALEZ GUILLERMO JULIO PADRO;;ALVAGE VICTORIA RAMIREZ;;PENA ARNALDO GARCIA;;CRUZ CARLOS ENRIQUE RUIZ;;LOPEZ GLADYS MABEL IZQUIERDO;;MARTINEZ LUIS SATURNINO HERRER;;CANO CAROLS ANTONIO DUARTE;;SUAREZ LILIA LUISA PEREZ;;CABALLERO JOSE GARCIA;;RIVA GUSTAVO ALBERTO DE LA RIV;;LASA ALEXIS SANTIAGO MUSACCHIO;;ZORRILLA FILIBERTO R AYON;;MEIRELES ROLANDO PAEZ;;FIERRO ALBERTO AGRAZ;;BETANCOURT RAUL E DIAZ;;MAYA YAIR QUINONES,,https://lens.org/053-590-339-987-592,Granted Patent,no,3,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
37,DE,T2,DE 69133525 T2,102-084-522-412-301,2006-11-23,2006,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/102-084-522-412-301,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
38,DE,D1,DE 69133525 D1,029-436-986-674-052,2006-06-01,2006,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/029-436-986-674-052,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
39,DE,T8,DE 69133525 T8,131-577-904-794-138,2007-03-08,2007,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/131-577-904-794-138,Amended Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
40,EP,A2,EP 0864649 A2,035-471-096-287-457,1998-09-16,1998,EP 98202021 A,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,"A multi-step process for recovering hepatitis B surface antigen from  Pichia   pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CIGB,MUZIO GONZALEZ VERENA L MUZIO;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;ALBAJES VICTORIA RAMIREZ;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/035-471-096-287-457,Patent Application,yes,0,1,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
41,DK,T3,DK 0864649 T3,056-054-526-484-237,2006-08-28,2006,DK 98202021 T,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ VERENA L;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESU;;GARCIA SUAREZ JOSE SAN REAFAE;;AYON ZORRILLA FILIBERTO ROSEND;;QUINONES MAYA YAIR;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;RAMIREZ ALBAJES VICTORIA,,https://lens.org/056-054-526-484-237,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
42,JP,A,JP 2001231582 A,057-022-638-447-65X,2001-08-28,2001,JP 2000392672 A,2000-12-25,CU 1990155 A,1990-10-08,RECOMBINANT SURFACE ANTIGEN OF HEPATITIS B VIRUS HAVING HIGHER IMMUNOGENIC COMPETENCE AND VACCINE COMPOSITION FOR IMMUNIZING AGAINST HEPATITIS B VIRUS,"PROBLEM TO BE SOLVED: To provide an remarkably homogeneous and particulate recombinant surface antigen of hepatitis B virus having higher immunogenic competence and derived from recombinant Pichia pastoris strain C226 [pTAO906], CBS450.90 and a vaccine composition for immunizing against hepatitis B virus, comprising recombinant hepatitis B surface antigen in an amount effective for vaccination, and at least one carrier, diluent or adjuvant suitable for use in a vaccine composition. SOLUTION: This recombinant hepatitis B surface antigen is obtained from recombinant Pichia pastoris strain C226 [pTAO906], CBS 450.90 containing a gene encoding the above hepatitis B surface antigen and having expressed the gene. This vaccine composition for immunizing against hepatitis B virus contains the above surface antigen as an active ingredient.",CT DE INGENIERIA GENETICA & BI,MUCIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;GALVEZ MARCELO NAZABAL;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;GONZALEZ GUILLERMO JULIO PADRO;;ALBAJES VICTORIA RAMIREZ;;GARCIA PENA ARNALDO;;CRUZ CARLOS ENRIQUE RUIZ;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;MEIRELES ROLANDO PAEZ;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;MAYA YAIR QUINONES,,https://lens.org/057-022-638-447-65X,Patent Application,no,0,0,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
43,DE,T2,DE 69130724 T2,164-079-995-222-586,1999-06-17,1999,DE 69130724 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/164-079-995-222-586,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
44,GR,T3,GR 3029582 T3,054-781-071-751-148,1999-06-30,1999,GR 990400666 T,1999-03-04,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B),,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/054-781-071-751-148,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
45,DE,D1,DE 69130724 D1,077-105-895-831-782,1999-02-18,1999,DE 69130724 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/077-105-895-831-782,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
46,EP,B1,EP 0480525 B1,052-642-419-326-095,1999-01-07,1999,EP 91202615 A,1991-10-07,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B),,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/052-642-419-326-095,Granted Patent,yes,1,3,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
47,AT,T1,AT E175445 T1,050-639-052-353-600,1999-01-15,1999,AT 91202615 T,1991-10-07,CU 1990155 A,1990-10-08,VERFAHREN ZUR GEWINNUNG VON REKOMBINANTEM HEPATITIS B VIRUS (HEP B) OBERFLÄCHEANTIGEN,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;ESQUINA ASUNCION;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;GERTRUDIS Y JOSEFINA;;HERRERA MARTINEZ LUIS;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/050-639-052-353-600,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,DISCONTINUED
48,AT,T1,AT E324451 T1,118-087-160-384-546,2006-05-15,2006,AT 98202021 T,1991-10-07,CU 1990155 A,1990-10-08,VERFAHREN ZUR HERSTELLUNG VON RECOMBINANTEM HEPATITIS B OBERFLÄCHENANTIGEN MIT ERHÖHTER IMMUNOGEN-KAPAZITÄT UND VERWENDUNG IN EINER IMPFSTOFFZUBEREITUNG,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ VERENA L;;ENTRE AVE Y NUEVO VEDADO;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;ESQUINA ASUNCION;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;GERTUDIS Y JOSEFINA;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;APTO CUBAY SAN IGNACIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;D STRAMPES Y GOICURIA;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/118-087-160-384-546,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
